NCT06869278 is a Phase 1 clinical trial of LCAR-AIO T cells in Multiple Sclerosis (MS), sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

What drugs are being tested in NCT06869278?

Interventions in NCT06869278: LCAR-AIO T cells.

What condition does NCT06869278 study?

NCT06869278 studies Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disease (NMOSD), Anti-Myelin Oligodendrocyte Glycoprotein-IgG Associated Disorders (MOGAD), Myasthenia Gravis.

Is NCT06869278 still recruiting?

NCT06869278 is currently recruiting now. Last updated 11 June 2025.

Last reviewed 2025-06-11 · How we verify

NCT06869278

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases

Recruiting now Phase 1 Last updated 11 June 2025

What this trial tests

Phase 1 trial testing LCAR-AIO T cells in Multiple Sclerosis (MS) in 37 participants. Currently enrolling.

Timeline

17 June 2025

Primary endpoint
30 June 2026

31 December 2029

Quick facts

Lead sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	37
Start date	17 June 2025
Primary completion	30 June 2026
Estimated completion	31 December 2029
Sites	3 locations across China

Drugs / interventions tested

LCAR-AIO T cells — full drug profile →

Conditions studied

Multiple Sclerosis (MS) — all drugs for Multiple Sclerosis (MS) →
Neuromyelitis Optica Spectrum Disease (NMOSD) — all drugs for Neuromyelitis Optica Spectrum Disease (NMOSD) →
Anti-Myelin Oligodendrocyte Glycoprotein-IgG Associated Disorders (MOGAD) — all drugs for Anti-Myelin Oligodendrocyte Glycoprotein-IgG Associated Disorders (MOGAD) →
Myasthenia Gravis — all drugs for Myasthenia Gravis →

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Who can join

Adults 18 to 70, any sex, with Multiple Sclerosis (MS) or Neuromyelitis Optica Spectrum Disease (NMOSD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory neurological autoimmune diseases.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Innovations in immunotherapy for autoimmune diseases: recent breakthroughs and future directions.
Alsayb MA. · · 2025 · cited 2× · PMID 41041324 · DOI 10.3389/fimmu.2025.1647066
Induction of immune tolerance in NMOSD and MOGAD.
Correale J, Carnero Contentti E. · · 2025 · cited 2× · PMID 40761287 · DOI 10.1177/17562864251357393
Roads and detours for CAR T cell therapy in autoimmune diseases.
Avouac J, Barzel A, Caiati D, Davis RS, et al · · 2026 · cited 1× · PMID 41588112 · DOI 10.1038/s41573-025-01349-4
Nanobodies in biomedicine: from molecular characteristics to fabrication and clinical translation.
Cao CK, Xu XY, Liang F, Yao M, et al · · 2026 · PMID 42063469 · DOI 10.1016/j.mmr.2026.100009
Neurological implications of chimeric antigen receptor-T cell therapy.
Raffoul DG, Roos I, Mulazzani M, Anderson MA, et al · · 2026 · PMID 41877734 · DOI 10.1136/bmjno-2025-001491
CAR T cell therapy in autoantibody-mediated neurological disorders: a promising strategy.
Wen M, Zheng R, Zhang H, Goldberg SY, et al · · 2026 · PMID 41821047 · DOI 10.1186/s12974-025-03662-6
CAR T-Cell Immunotherapy in Neuroautoimmune Diseases: Focus on the Central Nervous System
Demetriou F, Anagnostouli M. · · 2026
MOGAD: A Shifting Landscape-From Pathogenesis to Personalised Management, Global Perspectives and Latin American Insights.
Ciampi E. · · 2025 · PMID 41153632 · DOI 10.3390/biomedicines13102344

Verify or expand the search:

Other trials of LCAR-AIO T cells

Trials testing the same drug.

NCT06866080 — A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases · EARLY_PHASE1 · withdrawn
NCT06653556 — A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus · EARLY_PHASE1 · recruiting

Other recruiting trials for Multiple Sclerosis (MS)

Currently open trials in the same condition.

NCT07526493 — Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Media · Phase 1 · recruiting
NCT06053749 — An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimest · active not recruiting
NCT06270641 — Increasing Physical Activity for Adults With Multiple Sclerosis (MS) · NA · recruiting
NCT06157086 — Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France · active not recruiting
NCT05359653 — Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy · Phase 1, PHASE2 · recruiting

Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials

Trials by the same sponsor.

NCT07521124 — ABC Maintenance Therapy for AML · NA · not yet recruiting
NCT07497243 — X-ray Assisted Diagnostic System · not yet recruiting
NCT07520123 — Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatiti · NA · not yet recruiting
NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
NCT07509424 — Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Lo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06869278 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Last refreshed: 11 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06869278.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing